Antibiotic Resistance of MRSA in the Russian Federation

The results of the multicentre trial on estimation of MRSA antibiotic susceptibility to 17 antibiotics are presented. 474 nonrepeting isolates of MRSA (mecA+), collected in 2011-2014 in 10 cities of the Russian Federation were used in the trial. The antibiotic susceptibility was determined by the method of serial microdilutions in broth with estimation of the MICs in accordance with the international standards CLSI 2014 and EUCAST 2014. The highest levels of the MRSA resistance were stated against ciprofloxacin - 92% (MIC₅₀ 32 mcg/ml), gentamicin - 85% (MIC₅₀ 128 mcg/ml), erythromycin - 54% (MIC₅₀ 32 mcg/ml) and clindamycin - 45% (MIC₅₀ 0.03 mcg/ml), as well as against rifampicin - 38% (MIC₅₀ 0,06 mcg/ml). The frequency of MRSA isolated at the vancomycin dose of 2 mcg/ml equaled 26%. No correlation of the decrease in susceptibility to vancomycin and rifampicin was observed. In 5% of MRSA isolated from infected surgical wounds in patients with bone infection or sepsis, there was observed a decrease in the susceptibility to ceftarolin (MIC 2-4 mcg/ml). Co-trimoxasole, I'usidic acid (MIC₅₀ 0.06 mcg/ml) and mupirocin (MIC₅₀ 0.5 mcg/ml) showed high antibacterial activity, 93-98% of the isolates being susceptible to the drugs. No resistance to linezolid and tigecycline was detected. By the associate resistance spectrum, most of the MRSA isolates were characterized by resistance to drugs of 3-7 groups (56%). The phenotypes with simultaneous resistance to drugs of 8-10 groups amounted to 6%. As a whole, 70 variants of associate resistance combinations were detected.

antibiotics resistance, MRSA

1. CDC MRSA Statistics. Available from: http://www.cdc.gov/mrsa/statistics/index.html.

2. Howden B.P. et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 1: 99-139.

3. EARS-Net database. Available from: http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/database.aspx.

4. Kock R. et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15: 41: 19688.

5. Zhanel G.G. et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 2010; 70: 7: 859-886.

6. van Hal S.J., Paterson D.L. New Gram-positive antibiotics: better than vancomycin? Curr Opin Infect Dis 2011; 24: 6: 515-520.

7. Ageevets V.A. et al. Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia. Int J Antimicrob Agents 2014; 44: 2: 152-155.

8. Akatov A.K., Zueva V.S. Staphylococcus. AMS USSR,Moscow: Meditsina. 256.

9. Musina L.T. et al. Epidemiological surveillance of hospital infections induced by methicllin-resistant Staphylococcus aureus. Zh Mikrobiol 1995; 5: 64-67.

10. Сидоренко C.B., Резван С.П., Грудинина С.А., Кротова Л.А., Стерхова Г.В. Результаты многоцентрового исследования чувствительности стафилококков к антибиотикам в Москве и Санкт-Петербурге. Антибиотики и химиотер 1998; 43: 7: 15-25.

11. Дехнич А.В. и др. Эпидемиология резистентности штаммов S.aureus, выделенных от пациентов в ОРИТ Российских стационаров: результаты многоцентрового исследования. КМАХ 2008; 10: 4: 333-344.

12. Sukhorukova M.V. et al. Antimicrobial resistance of nosocomial Staphylococcus aureus isolates in Russia: results of national multicenter surveillance study «MARATHON» 2011-2012 CMAC, 2014; 16: 4: 280-286.

13. Дехнич А.В. и др. Эпидемиология антибиотикорезистентности нозокомиальных штаммов Staphylococcus aureus в России: результаты многоцентрового исследования. КМАХ 2002; 4: 4: 325-336.

14. Гостев В.В., Попенко Л.Н., Черненькая Т.В., Науменко З.С., Ворошилова Т.М., Захарова Ю.А., Хохлова O.E., Круглов А.Н., Ершова М.Г., Ангелова C.H., Полетаева Е.Д., Молчанова И.В., Сидоренко С.В. Оценка чувствительности MRSA к оксациллину, цефотаксиму, ванкомицину и даптомицину. Антибиотики и химиотер 2013; 58: 9-10: 13-20.

15. Watanabe Y. et al. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49: 7: 2680-2684.

16. Dhand A., Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy. F1000 Med Rep 2012; 4: 4.

17. Edwards B. et al. Is vancomycin MIC «creep» method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 2012; 50: 2: 318-325.

18. Joana S. et al. Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital. BMC Res Notes 2013; 6: 65.

19. Magiorakos A.P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 3: 268-281.